Benzinga | Aug 10, 2020 07:50AM EDT

Biohaven Pharmaceutical Q2 EPS $(2.55) Beats $(2.61) Estimate, Sales $9.70M Beat $7.65M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(2.55) per share which beat the analyst consensus estimate of $(2.61) by 2.3 percent. This is a 8.51 percent decrease over losses of $(2.35) per share from the same period last year. The company reported quarterly sales of $9.70 million which beat the analyst consensus estimate of $7.65 million by 26.77 percent.